ZD0473 treatment in lung cancer

An overview of the clinical trial results

J. Treat, J. Schiller, E. Quoix, A. Mauer, M. Edelman, M. Modiano, P. Bonomi, R. Ramlau, E. Lemarie

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

Original languageEnglish (US)
JournalEuropean Journal of Cancer
Volume38
Issue numberSUPPL. 8
StatePublished - 2002

Fingerprint

Meta-Analysis
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Platinum
Therapeutics
amminedichloro(2-methylpyridine)platinum(II)
Lethargy
Neutropenia
Thrombocytopenia
Dyspnea
Anemia
Recurrence

Keywords

  • Lung cancer
  • NSCLC
  • Platinum-resistant
  • Platinum-sensitive
  • SCLC
  • ZD0473

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Treat, J., Schiller, J., Quoix, E., Mauer, A., Edelman, M., Modiano, M., ... Lemarie, E. (2002). ZD0473 treatment in lung cancer: An overview of the clinical trial results. European Journal of Cancer, 38(SUPPL. 8).

ZD0473 treatment in lung cancer : An overview of the clinical trial results. / Treat, J.; Schiller, J.; Quoix, E.; Mauer, A.; Edelman, M.; Modiano, M.; Bonomi, P.; Ramlau, R.; Lemarie, E.

In: European Journal of Cancer, Vol. 38, No. SUPPL. 8, 2002.

Research output: Contribution to journalArticle

Treat, J, Schiller, J, Quoix, E, Mauer, A, Edelman, M, Modiano, M, Bonomi, P, Ramlau, R & Lemarie, E 2002, 'ZD0473 treatment in lung cancer: An overview of the clinical trial results', European Journal of Cancer, vol. 38, no. SUPPL. 8.
Treat J, Schiller J, Quoix E, Mauer A, Edelman M, Modiano M et al. ZD0473 treatment in lung cancer: An overview of the clinical trial results. European Journal of Cancer. 2002;38(SUPPL. 8).
Treat, J. ; Schiller, J. ; Quoix, E. ; Mauer, A. ; Edelman, M. ; Modiano, M. ; Bonomi, P. ; Ramlau, R. ; Lemarie, E. / ZD0473 treatment in lung cancer : An overview of the clinical trial results. In: European Journal of Cancer. 2002 ; Vol. 38, No. SUPPL. 8.
@article{4944d817017146a8a342d203f8ca0e93,
title = "ZD0473 treatment in lung cancer: An overview of the clinical trial results",
abstract = "Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8{\%}, 22.2{\%} and 27.7{\%} of first-line NSCLC patients; 12.0{\%}, 24.0{\%} and 50{\%} of second-line NSCLC patients; and 10.4{\%}, 25.0{\%} and 47.9{\%} of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3{\%}. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4{\%} and 8.3{\%} were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.",
keywords = "Lung cancer, NSCLC, Platinum-resistant, Platinum-sensitive, SCLC, ZD0473",
author = "J. Treat and J. Schiller and E. Quoix and A. Mauer and M. Edelman and M. Modiano and P. Bonomi and R. Ramlau and E. Lemarie",
year = "2002",
language = "English (US)",
volume = "38",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "SUPPL. 8",

}

TY - JOUR

T1 - ZD0473 treatment in lung cancer

T2 - An overview of the clinical trial results

AU - Treat, J.

AU - Schiller, J.

AU - Quoix, E.

AU - Mauer, A.

AU - Edelman, M.

AU - Modiano, M.

AU - Bonomi, P.

AU - Ramlau, R.

AU - Lemarie, E.

PY - 2002

Y1 - 2002

N2 - Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

AB - Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

KW - Lung cancer

KW - NSCLC

KW - Platinum-resistant

KW - Platinum-sensitive

KW - SCLC

KW - ZD0473

UR - http://www.scopus.com/inward/record.url?scp=0036983552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036983552&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - SUPPL. 8

ER -